AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease
Niemann-Pick type C disease (NP-C) is a fatal neurodegenerative lysosomal storage disorder. It is caused in 95% of cases by a mutation in the NPC1 gene that encodes NPC1, an integral transmembrane protein localised to the limiting membrane of the lysosome. There is no cure for NP-C but there is a di...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 出版: |
Oxford University Press
2018
|
| _version_ | 1826268611622207488 |
|---|---|
| author | Hughes, MP Smith, DA Morris, L Fletcher, C Colaco, A Huebecker, M Tordo, J Palomar, N Massaro, G Henckaerts, E Waddington, SN Platt, FM Rahim, AA |
| author_facet | Hughes, MP Smith, DA Morris, L Fletcher, C Colaco, A Huebecker, M Tordo, J Palomar, N Massaro, G Henckaerts, E Waddington, SN Platt, FM Rahim, AA |
| author_sort | Hughes, MP |
| collection | OXFORD |
| description | Niemann-Pick type C disease (NP-C) is a fatal neurodegenerative lysosomal storage disorder. It is caused in 95% of cases by a mutation in the NPC1 gene that encodes NPC1, an integral transmembrane protein localised to the limiting membrane of the lysosome. There is no cure for NP-C but there is a disease-modifying drug (miglustat) that slows disease progression but with associated side effects. Here, we demonstrate in a well-characterised mouse model of NP-C that a single administration of AAV-mediated gene therapy to the brain can significantly extend lifespan, improve quality of life, prevent or ameliorate neurodegeneration, reduce biochemical pathology and normalize or improve various indices of motor function. Over-expression of human NPC1 does not cause adverse effects in the brain and correctly localises to late endosomal/lysosomal compartments. Furthermore, we directly compare gene therapy to licensed miglustat. Even at a low dose, gene therapy has all the benefits of miglustat but without adverse effects. On the basis of these findings and on-going ascendency of the field, we propose intracerebroventricular gene therapy as a potential therapeutic option for clinical use in NP-C. |
| first_indexed | 2024-03-06T21:12:21Z |
| format | Journal article |
| id | oxford-uuid:3e9b4d19-2e70-456b-b5e0-68735e687c94 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T21:12:21Z |
| publishDate | 2018 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:3e9b4d19-2e70-456b-b5e0-68735e687c942022-03-26T14:26:36ZAAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3e9b4d19-2e70-456b-b5e0-68735e687c94Symplectic Elements at OxfordOxford University Press2018Hughes, MPSmith, DAMorris, LFletcher, CColaco, AHuebecker, MTordo, JPalomar, NMassaro, GHenckaerts, EWaddington, SNPlatt, FMRahim, AANiemann-Pick type C disease (NP-C) is a fatal neurodegenerative lysosomal storage disorder. It is caused in 95% of cases by a mutation in the NPC1 gene that encodes NPC1, an integral transmembrane protein localised to the limiting membrane of the lysosome. There is no cure for NP-C but there is a disease-modifying drug (miglustat) that slows disease progression but with associated side effects. Here, we demonstrate in a well-characterised mouse model of NP-C that a single administration of AAV-mediated gene therapy to the brain can significantly extend lifespan, improve quality of life, prevent or ameliorate neurodegeneration, reduce biochemical pathology and normalize or improve various indices of motor function. Over-expression of human NPC1 does not cause adverse effects in the brain and correctly localises to late endosomal/lysosomal compartments. Furthermore, we directly compare gene therapy to licensed miglustat. Even at a low dose, gene therapy has all the benefits of miglustat but without adverse effects. On the basis of these findings and on-going ascendency of the field, we propose intracerebroventricular gene therapy as a potential therapeutic option for clinical use in NP-C. |
| spellingShingle | Hughes, MP Smith, DA Morris, L Fletcher, C Colaco, A Huebecker, M Tordo, J Palomar, N Massaro, G Henckaerts, E Waddington, SN Platt, FM Rahim, AA AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease |
| title | AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease |
| title_full | AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease |
| title_fullStr | AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease |
| title_full_unstemmed | AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease |
| title_short | AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease |
| title_sort | aav9 intracerebroventricular gene therapy improves lifespan locomotor function and pathology in a mouse model of niemann pick type c1 disease |
| work_keys_str_mv | AT hughesmp aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT smithda aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT morrisl aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT fletcherc aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT colacoa aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT huebeckerm aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT tordoj aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT palomarn aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT massarog aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT henckaertse aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT waddingtonsn aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT plattfm aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease AT rahimaa aav9intracerebroventriculargenetherapyimproveslifespanlocomotorfunctionandpathologyinamousemodelofniemannpicktypec1disease |